TalaricoLR, SchatzbergSJ. Idiopathic granulomatous and necrotising inflammatory disorders of the canine central nervous system: a review and future perspectives. J Small Anim Pract 2010;51:138–149.10.1111/j.1748-5827.2009.00823.x)| false
KiparA, BaumgärtnerW, VoglC, Immunohistochemical characterization of inflammatory cells in brains of dogs with granulomatous meningoencephalitis. Vet Pathol 1998;35:43–52.10.1177/030098589803500104)| false
GrangerN, SmithPM, JefferyND. Clinical findings and treatment of non-infectious meningoencephalomyelitis in dogs: a systematic review of 457 published cases from 1962 to 2008. Vet J 2010;184:290–297.10.1016/j.tvjl.2009.03.031)| false
AdamoPF, RylanderH, AdamsWM. Ciclosporin use in multi-drug therapy for meningoencephalomyelitis of unknown aetiology in dogs. J Small Anim Pract 2007;48:486–496.10.1111/j.1748-5827.2006.00303.x)| false
FlegelT, OevermannA, OechteringG, Diagnostic yield and adverse effects of MRI-guided free-hand brain biopsies through a mini-burr hole in dogs with encephalitis. J Vet Intern Med 2012;26:969–976.10.1111/j.1939-1676.2012.00961.x)| false
StaffordEG, KortumA, CastelA, Presence of cerebro-spinal fluid antibodies associated with autoimmune encephalitis of humans in dogs with neurologic disease. J Vet Intern Med 2019;33:2175–2182.10.1111/jvim.15616)| false
IorioR, DamatoV, EvoliA, Clinical and immunological characteristics of the spectrum of GFAP autoimmunity: a case series of 22 patients. J Neurol Neurosurg Psychiatry 2018;89:138–146.10.1136/jnnp-2017-316583)| false
FlanaganEP, HinsonSR, LennonVA, Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol 2017;81:298–309.10.1002/ana.24881)| false
ShibuyaM, MatsukiN, FujiwaraK, et al.Autoantibodies against glial fibrillary acidic protein (GFAP) in cerebrospinal fluids from Pug dogs with necrotizing meningoencephalitis. J Vet Med Sci2007;69:241–245.
ShibuyaM, MatsukiN, FujiwaraK, Autoantibodies against glial fibrillary acidic protein (GFAP) in cerebrospinal fluids from Pug dogs with necrotizing meningoencephalitis. J Vet Med Sci 2007;69:241–245.10.1292/jvms.69.241)| false
ZhangZ, ZoltewiczJ, MondelloS, Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One 2014;9:e92698.10.1371/journal.pone.0092698)| false
LiuT, ChenB, YangH, et al.Screening for autoantibodies in inflammatory neurological syndrome using fluorescence pattern in a tissue-based assay: cerebrospinal fluid findings from 793 patients. Mult Scler Relat Disord2019;28:177–183.
LiuT, ChenB, YangH, Screening for autoantibodies in inflammatory neurological syndrome using fluorescence pattern in a tissue-based assay: cerebrospinal fluid findings from 793 patients. Mult Scler Relat Disord 2019;28:177–183.10.1016/j.msard.2018.12.036)| false
Evaluation of cell-based and tissue-based immunofluorescent assays for detection of glial fibrillary acidic protein autoantibodies in the cerebrospinal fluid of dogs with meningoencephalitis of unknown origin and other central nervous system disorders
To evaluate whether cell-based and tissue-based immunofluorescent assays (IFAs) run in parallel could be used to detect glial fibrillary acidic protein (GFAP) autoantibodies in the CSF of dogs with meningoencephalitis of unknown origin (MUO) and other CNS disorders
15 CSF samples obtained from dogs with presumed MUO (n = 5), CNS disease other than MUO (5), and idiopathic epilepsy (5).
All CSF samples underwent parallel analysis with a cell-based IFA that targeted the α isoform of human GFAP and a tissue-based IFA that involved mouse brain cryosections. Descriptive data were generated.
Only 1 CSF sample yielded mildly positive results on the cell-based IFA; that sample was from 1 of the dogs with presumed MUO. The remaining 14 CSF samples tested negative on the cell-based IFA. All 15 CSF samples yielded negative results on the tissue-based IFA.
CONCLUSIONS AND CLINICAL RELEVANCE
Results suggested that concurrent use of a cell-based IFA designed to target the human GFAP-α isoform and a tissue-based IFA that involved mouse tissue cryosections was inadequate for detection of GFAP autoantibodies in canine CSF samples. Given that GFAP autoantibodies were likely present in the CSF samples analyzed, these findings suggested that epitopes differ substantially between canine and human GFAP and that canine GFAP autoanti-body does not bind to mouse GFAP. Without a positive control, absence of GFAP autoantibody in this cohort cannot be ruled out. Further research is necessary to develop a noninvasive and sensitive method for diagnosis of MUO in dogs.
Dr. Mooney's present address is the Mississippi State University Veterinary Specialty Center, Starkville MS, 39759.